ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Emgality (galcanezumab) by Year
Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Emgality (galcanezumab): $870M in FY2024, up 28.3% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Emgality | 559.7 | 310.7 | 870.4 | 678.3 | 28”
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 870 | +28.3% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 678 | +4.2% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 651 | +12.8% | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 577 | +59.1% | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 363 | +123.3% | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 163 | +3,216.3% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 4.90 | – | Form 10-K FY2019 (filed 2020-02-19) ↗ |
Breakdown
What makes up emgality (galcanezumab)
Cite this data
StockData. (2026). Eli Lilly Emgality (galcanezumab) ($M), annual FY2018–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-emgality-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.